Grifols reported EUR156.07M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Arca Biopharma USD 4.6M 4.1M Mar/2026
aTyr Pharma 59.81M 10.02M Sep/2026
Bio Path 677K 547K Mar/2026
Capricor Therapeutics 3.05M 2.46M Dec/2025
Cara Therapeutics 23.53M 113.18M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Grifols EUR 156.07M 31.46M Sep/2025
Immunic 197K 222K Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
TherapeuticsMD USD 20K 25K Sep/2023